Shumei Kato

Also affiliated with University of California San Diego, Center for Personalized Cancer Treatment, Moores Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine

JCO Precision Oncology(2022)10.1200/po.20.00508

Top 22%

0.918DataRank

Top 22%17 citations

Ramez N. Eskander, Jason K. Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +8 more

Papers

Driven by 51 papers — median percentile 53. Top paper: “SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer”.

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer

JCI Insight(2021)10.1172/jci.insight.150453

N/A

2.2DataRank · unranked

68 citations

Shumei Kato, Hitendra Patel, Paul T. Fanta, Suzanna Lee, Ryosuke Okamura +2 more

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

Genome Medicine(2021)10.1186/s13073-021-00969-w

N/A

1.9DataRank · unranked

90 citations

Shumei Kato, Ryosuke Okamura, Hitendra Patel, Mina Nikanjam, Paul T. Fanta +14 more

Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens

JCI Insight(2021)10.1172/jci.insight.142547

N/A

1.1DataRank · unranked

31 citations

Ryosuke Okamura, Jacob J. Adashek, Noor Khalid, Suzanna Lee, Van Thomas Nguyen +3 more

Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine

JCO Precision Oncology(2022)10.1200/po.20.00508

Top 22%

0.918DataRank

Top 22%17 citations

Ramez N. Eskander, Jason K. Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +8 more

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers

Molecular Cancer Therapeutics(2020)10.1158/1535-7163.mct-20-0161

N/A

0.700DataRank · unranked

105 citations

Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzanna Lee +9 more

Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0270

N/A

0.457DataRank · unranked

9 citations

Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro +6 more

ICOS and ICOS ligand: expression patterns and outcomes in oncology patients

Therapeutic Advances in Medical Oncology(2025)10.1177/17588359251330514

N/A

0.343DataRank · unranked

8 citations

Shumei Kato, Daisuke Nishizaki, Donald A. Barkauskas, Sarabjot Pabla, Mary Nesline +4 more

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies

npj Precision Oncology(2022)10.1038/s41698-022-00259-7

Top 71%

0.123DataRank

Top 71%1 citations

Razelle Kurzrock, Suzanna Lee, Ryosuke Okamura, Hyo Jeong Lim, Ki Hwan Kim +3 more

Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1077

N/A

0DataRank · unranked

7 citations

Hatem Soliman, Siqing Fu, Karen A. Gelmon, Albiruni Ryan Abdul Razak, Pamela N. Münster +11 more

Targeting G1-S phase cell-cycle alterations with CDK4/6 inhibitor-based genomically matched personalized therapy approach.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3623

N/A

0DataRank · unranked

1 citations

Shumei Kato, Ryosuke Okamura, Noor Khalid, Suzanna Lee, Van Thomas Nguyen +3 more

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Nature Reviews Clinical Oncology(2021)10.1038/s41571-021-00487-z

N/A

0DataRank · unranked

140 citations

Justin F. Gainor, Aparna Hegde, Alison M. Schram, Giuseppe Curigliano, Sumanta K. Pal +19 more

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3761

N/A

0DataRank · unranked

41 citations

Jacob J. Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee +3 more

Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1221

N/A

0DataRank · unranked

32 citations

Jorge de la Torre Cantero, Nikki S. IJzerman, Thomas L. Sutton, Beiqun Zhao, Tahsin M. Khan +25 more

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐freeDNAin invasive gliomas after treatment

International Journal of Cancer(2021)10.1002/ijc.33481

N/A

0DataRank · unranked

31 citations

David Piccioni, Amélie Boichard, Suzanna Lee, Rebecca E. Jimenez, Jason K. Sicklick +3 more

KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery

The Oncologist(2021)10.1002/onco.13702

N/A

0DataRank · unranked

14 citations

Thomas McFall, Kenta Takahashi, Kasey Bamel, Sadakatsu Ikeda, Ramez N. Eskander +5 more

Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8563

N/A

0DataRank · unranked

0 citations

Marc R. Radke, Navid Hafez, Hatem Soliman, Siqing Fu, Shumei Kato +11 more

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy

npj Precision Oncology(2022)10.1038/s41698-022-00309-0

N/A

0DataRank · unranked

17 citations

Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Ramez N. Eskander +7 more

Multi‐omic analysis in carcinoma of unknown primary ( CUP ): therapeutic impact of knowing the unknown

Molecular Oncology(2022)10.1002/1878-0261.13293

N/A

0DataRank · unranked

12 citations

Sophia Gumas, Jacob J. Adashek, Ryosuke Okamura, Suzanna Lee, Jason K. Sicklick +2 more

Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards

Surgical Oncology Clinics of North America(2023)10.1016/j.soc.2023.12.004

N/A

0DataRank · unranked

14 citations

Shumei Kato, Razelle Kurzrock, Yu Fujiwara

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics

Cancer Medicine(2023)10.1002/cam4.6000

N/A

0DataRank · unranked

32 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Pradip De, Suzanna Lee +7 more

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study

npj Precision Oncology(2023)10.1038/s41698-022-00341-0

N/A

0DataRank · unranked

22 citations

Jason Roszik, Filip Jankú, David S. Hong, Shumei Kato, Aung Naing +11 more

T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

npj Genomic Medicine(2023)10.1038/s41525-023-00359-8

N/A

0DataRank · unranked

21 citations

Razelle Kurzrock, Nicholas Bevins, Kartheeswaran Thangathurai, Suzanna Lee, Sarabjot Pabla +8 more

Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity

Cancer Medicine(2023)10.1002/cam4.6844

N/A

0DataRank · unranked

13 citations

Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Jacob J. Adashek, Suzanna Lee +7 more

At the right dose: personalised (N-of-1) dosing for precision oncology

European Journal of Cancer(2023)10.1016/j.ejca.2023.113359

N/A

0DataRank · unranked

12 citations

Shumei Kato, Jason K. Sicklick, Razelle Kurzrock, Mina Nikanjam

Considering molecular alterations as pan-cancer tissue-agnostic targets

Nature Cancer(2023)10.1038/s43018-023-00676-y

N/A

0DataRank · unranked

11 citations

Shumei Kato, Jason K. Sicklick, Scott M. Lippman, Razelle Kurzrock, Jacob J. Adashek

Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy

Research Square(2023)10.21203/rs.3.rs-2551645/v1

N/A

0DataRank · unranked

2 citations

Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro +6 more

Data from Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

(2023)10.1158/1078-0432.c.6529977

N/A

0DataRank · unranked

0 citations

Jacob J. Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee +3 more

Data from Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity

(2023)10.1158/1078-0432.c.6530702

N/A

0DataRank · unranked

0 citations

Jorge de la Torre, Nikki S. IJzerman, Thomas L. Sutton, Beiqun Zhao, Tahsin M. Khan +25 more

Data from Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity

(2023)10.1158/1078-0432.c.6530702.v1

N/A

0DataRank · unranked

0 citations

Jorge de la Torre, Nikki S. IJzerman, Thomas L. Sutton, Beiqun Zhao, Tahsin M. Khan +25 more

Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2614

N/A

0DataRank · unranked

0 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

Viewing the immune checkpoint VISTA: landscape and outcomes across cancers

ESMO Open(2024)10.1016/j.esmoop.2024.102942

N/A

0DataRank · unranked

31 citations

Razelle Kurzrock, Hirotaka Miyashita, Jacob J. Adashek, Suzanna Lee, Mina Nikanjam +10 more

If it’s a target, it’s a pan-cancer target: Tissue is not the issue

Cancer Treatment Reviews(2024)10.1016/j.ctrv.2024.102721

N/A

0DataRank · unranked

29 citations

Shumei Kato, Jason K. Sicklick, Scott M. Lippman, Razelle Kurzrock, Jacob J. Adashek

Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategy

iScience(2024)10.1016/j.isci.2024.110465

N/A

0DataRank · unranked

10 citations

Shumei Kato, Jordan S. Lim, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +6 more

High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy

iScience(2024)10.1016/j.isci.2024.109632

N/A

0DataRank · unranked

10 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses

Med(2024)10.1016/j.medj.2024.04.008

N/A

0DataRank · unranked

7 citations

Kaitlyn Wells, Shumei Kato, Jacob J. Adashek, Shanna Block, Razelle Kurzrock +1 more

4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists

Cancer Communications(2024)10.1002/cac2.12592

N/A

0DataRank · unranked

4 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +7 more

Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.2626

N/A

0DataRank · unranked

1 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +5 more

Toll-like receptor 3: a double-edged sword

Biomarker Research(2025)10.1186/s40364-025-00739-5

N/A

0DataRank · unranked

33 citations

Daisuke Nishizaki, Jacob J. Adashek, Shumei Kato, Razelle Kurzrock, Marvin L Hsieh

Novel clinical trial designs emerging from the molecular reclassification of cancer

CA A Cancer Journal for Clinicians(2025)10.3322/caac.21880

N/A

0DataRank · unranked

11 citations

Shumei Kato, Teresa Allen, Jason K. Sicklick, Razelle Kurzrock, Mina Nikanjam

Inducible T‐Cell Co‐Stimulator ( ICOS ) and ICOS Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System

Cancer Medicine(2025)10.1002/cam4.71467

N/A

0DataRank · unranked

5 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Sarabjot Pabla, Mary Nesline +5 more

Tumor mutational burden, PD-1, negative Wnt/β-catenin regulators, and positive MHC class II antigen presentation regulators as predictors of longer survival after immune checkpoint inhibitors across cancers: A comprehensive analysis of 400 immunity biomarkers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2625

N/A

0DataRank · unranked

0 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

Natural killer cell transcriptomic expression and prediction of survival after immune checkpoint blockade across cancers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2518

N/A

0DataRank · unranked

0 citations

Daisuke Nishizaki, Suzanna Lee, Taylor J. Jensen, Shumei Kato, Paul DePietro +3 more

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000438

N/A

0DataRank · unranked

191 citations

Shumei Kato, Suzanna Lee, Rebecca E. Jimenez, Jason K. Sicklick, Razelle Kurzrock +1 more

Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies

Research Square(2025)10.21203/rs.3.rs-5135027/v1

N/A

0DataRank · unranked

0 citations

Tadashi Manabe, Hannah C. Bergo, Qingtian Li, Tim Sen Wang, Paul Severson +19 more

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Nature Communications(2020)10.1038/s41467-020-18613-3

N/A

0DataRank · unranked

303 citations

Ki Hwan Kim, Hyo Jeong Lim, Amélie Boichard, Mina Nikanjam, Elizabeth Weihe +17 more

MHC-I genotype and tumor mutational burden predict response to immunotherapy

Genome Medicine(2020)10.1186/s13073-020-00743-4

N/A

0DataRank · unranked

115 citations

Andrea Castro, Rachel Marty Pyke, Ryosuke Okamura, Shumei Kato, Paul Riviere +7 more

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers

International Journal of Cancer(2020)10.1002/ijc.33230

N/A

0DataRank · unranked

75 citations

Razelle Kurzrock, Robert J. Mallory, Paul T. Fanta, Adam M. Burgoyne, Bryan M. Clary +3 more

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

OncoImmunology(2020)10.1080/2162402x.2019.1708065

N/A

0DataRank · unranked

68 citations

Ryosuke Okamura, Yuichi Kumaki, Sadakatsu Ikeda, Mina Nikanjam, Ramez N. Eskander +9 more

Precision oncology: the intention-to-treat analysis fallacy

European Journal of Cancer(2020)10.1016/j.ejca.2020.04.002

N/A

0DataRank · unranked

8 citations

Shumei Kato, Ryosuke Okamura, Razelle Kurzrock, Jason K. Sicklick

Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience

The Oncologist(2020)10.1002/onco.13532

N/A

0DataRank · unranked

8 citations

Jason K. Sicklick, Shumei Kato, Ryosuke Okamura, Vincent A. Miller, Brian Leyland‐Jones +3 more

Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9065

N/A

0DataRank · unranked

10 citations

Navid Hafez, Hatem Soliman, Siqing Fu, Shumei Kato, Primo N. Lara +12 more

Shumei Kato

Indexed papers

Top data-sharing exemplar

Papers